Kailos Genetics

Kailos Genetics is a private, commercial-stage diagnostics company enabling precision medicine through integrated genetic testing services and reagent products. Its core business is built on a dual model: offering direct-to-provider clinical tests like Expedio™ for hereditary cancer and Inspexion™ for pharmacogenomics, while also supplying clinical-grade NGS reagents and bioinformatics software to research labs via its Kailos Complete™ and Kailos Flex™ programs. The company's strategy centers on making advanced genetic analysis more accessible and customizable for both clinical and research settings, positioning itself in the growing markets of preventive oncology and personalized drug therapy.

Proprietary TargetRich™ enrichment technology for targeted next-generation sequencing (NGS), integrated with cloud-based bioinformatics software for data analysis. This platform supports both clinical diagnostic tests and research reagent products.

Kailos competes in the crowded hereditary cancer testing space against giants like Myriad Genetics, Invitae, and Ambry Genetics, and in pharmacogenomics against companies like OneOme and Genomind. In the research reagent market, it competes with NGS platform leaders like Illumina and Thermo Fisher. Its differentiation lies in its integrated reagent-plus-software solutions and customizable panel options.